ARVN001 (triamcinolone acetonide suprachoroidal injectable suspension)

ARVN001 (triamcinolone acetonide suprachoroidal injectable suspension), known as XIPERE™ in the US and Canada, is a proprietary suspension of the corticosteroid triamcinolone acetonide formulated for administration to the back of the eye for the treatment of macular edema associated with uveitis. This patented technology is designed to deliver drug to the suprachoroidal space located between the choroid and the outer protective layer of the eye, known as the sclera. Suprachoroidal injection enables the rapid and adequate dispersion of medicine to the back of the eye, offering the potential for the medicine to act longer and minimize harm to the surrounding healthy parts of the eye. 

We are currently developing ARVN001 for the treatment of macular edema associated with uveitis to bring this novel therapy to our patients.